Switch to Health Care Professionals
Email Page
Print PageHerceptin Access Solutions—Committed to Helping You Access Herceptin (trastuzumab)
- Useful Links
- Forms and Documents
Understanding how to access and pay for your medication can be challenging. Herceptin Access Solutions is here to help you understand your options and the process.
Coverage and Reimbursement
Herceptin Access Solutions helps resolve specific access and reimbursement issues for individual patients every day. Our specialists are passionate about helping you access Herceptin and exploring every appropriate solution to coverage or reimbursement issues.
Patient Assistance
To learn more about our patient assistance programs, please click on the button that applies to you.
- I’m uninsured or my health insurance denied my coverage
- I have health insurance and need help with my co-pay*
If you have questions about your disease and your Herceptin treatment, the CancerCare Program can offer counseling, education and practical help free of charge. For more information, click here.
Informational Resources
We all know it’s important to have the right information at your fingertips. With this in mind, we’ve compiled a list of informational resources you may find useful.
Herceptin (trastuzumab) Indications
Adjuvant indications: Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature)* breast cancer:
- As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
- With docetaxel and carboplatin
- As a single agent following multi-modality anthracycline-based therapy
*ER/PR-negative, tumor size >2 cm, age <35 years, or histological and/or nuclear grade 2 or 3.
Metastatic indications: Herceptin is indicated:
- In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
- As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Herceptin Boxed WARNINGS and Additional Important Safety Information
Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. Herceptin can cause oligohydramnios and fetal harm when administered to a pregnant woman. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.
Please see the Herceptin full prescribing information including Boxed WARNINGS and additional important safety information.
*Co-pay refers to a cost-sharing arrangement in which members of health insurance plans pay a specified charge for a product or service, such as a prescription or an office visit. Members are typically responsible for this payment at the time of service.
Privacy information: Any information submitted to Herceptin Access Solutions will remain confidential and will not be used for promotional purposes.
If you would like to learn more about protecting the privacy of personal health information, please go to the U.S. Department of Health & Human Services website at www.hhs.gov/ocr/hipaa/.
